NEW PRAGUE, Minn. / Jan 24, 2024 / Business Wire / Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the virtual 2024 Lytham Partners Investor Select Conference on February 1, 2024.
Electromed’s management team will engage in a fireside chat and investor 1x1s. The fireside chat is scheduled to take place at 11 am Eastern Time on February 1, 2024. To register for the fireside chat, please click here.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
| Last Trade: | US$29.34 |
| Daily Change: | 1.27 4.52 |
| Daily Volume: | 33,796 |
| Market Cap: | US$246.460M |
November 12, 2024 October 28, 2024 August 27, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
